a maverick drugs industry entrepreneur may be about to prove his detractors wrong with a cancer drug that appears to be as good as existing treatments but without severe side-effects the drug will be submitted for regulatory approval in the first quarter of 1995 and could be on sale in europe by 1996 dr david horrobin's company scotia pharmaceuticals yesterday published final-stage clinical trial results on ef13 a pancreatic cancer drug which show that the life expectancy of cancer sufferers increased by up to two-thirds compared with patients on chemotherapy shares in scotia pharmaceuticals rose 21 p to 274 p after the company presented its results to city analysts with the price rise scotia has become the uk's second biggest biotechnology company by market capitalisation cancer experts gave the results a cautious welcome professor gordon mcvie scientific director at the cancer research campaign a london-based charity said the results were encouraging but he pointed out that the trials which compared ef13 with historic data on mortality would have been more convincing if the drug had been compared with a placebo in which neither doctor nor patient knew what was being administered scotia said the promising preliminary trial data meant there were ethical problems in knowingly withholding the drug from sufferers professor karol sikora cancer consultant at hammersmith hospital london said the results were interesting but that much more evaluation was needed cancer of the pancreas is one of the deadliest forms of the disease with about 60,000 deaths a year in europe and north america the historic data suggest that with the normal treatment regime in the uk average life expectancy is just over three months with the intensive chemotherapy sometimes used in the us the figure is seven months with high doses of ef13 patients survived for a year on average as the trial was not placebo-controlled it is possible that patients on ef13 survived longer because they had been selected for being stronger or because doctors gave them extra attention success for the drug would vindicate dr horrobin's championing of an obscure corner of chemistry dealing with fatty acids normally drug research is based on protein chemistry the former professor of medicine at montreal university began by selling evening primrose oil a natural source of fatty acids in health food shops and used the profits to establish research centres and manufacturing plants in nova scotia canada and the western isles of scotland he developed three drugs for treating skin conditions